When I joined Natus, I was impressed by the pace at which the Company had grown and gained leading positions in its markets. Kennedy said, “I am honored to lead Natus during this pivotal time in the Company’s history. I have known and worked with Jonathan for several years and am confident that he is the right leader to keep Natus moving forward and delivering market leading products and solutions to our customers and creating value for our shareholders. I am proud of all that we have accomplished in building Natus into the market leader it is today. Hawkins said, “It has been a privilege to serve as Natus’ CEO over the past 14 years and I thank Natus’ talented employees for their hard work and partnership on this journey.
No one is better prepared than Jonathan to lead Natus into its next phase of growth and value creation and the Board has the utmost confidence in him.” “He has diverse experience leading both technology and medical device companies, spearheading acquisition integration efforts and developing and implementing cost reduction initiatives on a worldwide basis. “Jonathan is a proven leader with a deep understanding of our business operations and a clear vision for the future,” said Dr. Paul, Chairperson of the Natus Board of Directors. Jim leaves Natus financially sound with attractive market opportunities and an experienced and stable management team,” said Dr. Jim has been a visionary leader who transformed Natus into the strong global company it is today. “On behalf of the Board of Directors, I would like to thank Jim Hawkins for his service and many contributions to Natus. was appointed Chairperson of the Natus Board of Directors. In addition, the Company announced that Barbara Paul, M.D. Kennedy has also been appointed to the Natus Board of Directors. As part of a planned succession, Jonathan Kennedy, who has served as Chief Financial Officer since April 2013, has been appointed President and Chief Executive Officer, effective immediately. During this time, Natus’ market capitalization has grown from approximately $70 million to $1.2 billion. During Jim’s leadership of Natus, the Company has grown from $30 million in annual revenue and a single product offering to over $500 million in annual revenue offering comprehensive products and solutions in the neurology and neurodiagnostics, newborn care and diagnostic hearing markets. PLEASANTON, Calif., J(GLOBE NEWSWIRE) - Natus Medical Incorporated (NASDAQ:BABY) (“The Company”) today announced that Jim Hawkins is retiring from Natus after 14 years of service as CEO. Releases Preliminary Q2 2018 Revenue and Conference Call Date Jonathan Kennedy Appointed President and Chief Executive Officerīoard Appoints Barbara Paul, M.D.
Jim Hawkins Retires after 14 years as President and CEO
0 kommentar(er)
